Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies
- 30 September 2001
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 15 (3), 133-142
- https://doi.org/10.1054/blre.2001.0160
Abstract
No abstract availableThis publication has 68 references indexed in Scilit:
- Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesisBlood, 2000
- Arsenic-Induced Apoptosis in Malignant CellsIn vitroLeukemia & Lymphoma, 2000
- Malignant Cells Can Be Sensitized to Undergo Growth Inhibition and Apoptosis by Arsenic Trioxide Through Modulation of the Glutathione Redox SystemBlood, 1999
- Arsenic Trioxide and Melarsoprol Induce Programmed Cell Death in Myeloid Leukemia Cell Lines and Function in a PML and PML-RAR Independent MannerBlood, 1998
- Arsenic Trioxide as an Inducer of Apoptosis and Loss of PML/RARα Protein in Acute Promyelocytic Leukemia CellsJNCI Journal of the National Cancer Institute, 1998
- Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemiaProceedings of the National Academy of Sciences, 1997
- The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RARCell, 1991
- Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemiaBlood, 1988
- CHRONIC ARSENICAL POISONING DURING THE TREATMENT OF CHRONIC MYELOID LEUKEMIAArchives of Internal Medicine, 1937
- ARSENIC AS A THERAPEUTIC AGENT IN CHRONIC MYELOGENOUS LEUKEMIAJAMA, 1931